Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ANDERSON, R. J.
Right arrow Articles by RAINES, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ANDERSON, R. J.
Right arrow Articles by RAINES, A.
NEUROLOGY 1976;26:858
© 1976 American Academy of Neurology

Suppression of decerebrate rigidity by phenytoin and chlorpromazine

REBECCA J. ANDERSON, Ph.D. and ARTHUR RAINES, Ph.D.

From the Department of Pharmacology, Georgetown University Schools of Medicine and Dentistry, 3900 Reservoir Road, N.W., Washington, DC.

In cats decerebrated by a midcollicular section, decerebrate rigidity developed that was not alleviated by phenytoin even in doses as great as 60 mg per kilogram. Chlorpromazine that depresses decerebrate rigidity in a dose-related fashion requires 1.5 to 2.0 mg per kilogram to exhibit an appreciable effect. In the presence of 20 mg per kilogram phenytoin, however, as little as 0.1 mg per kilogram chlorpromazine markedly reduces decerebrate rigidity. This drug combination did not impair neuromuscular transmission nor did it severely impair motor coordination in cats. Although phenytoin depressed muscle spindle discharges, this peripheral suppression was insufficient to abolish the rigidity. Phenytoin with or without chlorpromazine may be of value in suppressing muscle rigidity in some disorders of upper motor neuron lesions.

Dr. Raines' address is Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20007.

Dr. Anderson's present address is Department of Physiology, University of Toronto, Toronto, Canada.

This study was supported by USPHS grant No. RO 1 NS 100667-01A1.

Received for publication November 14, 1975.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by AAN Enterprises, Inc.